The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts.

This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts their potential impacts on the American pharmaceutical industry. Numerous tables and figures regarding the Medicare age population, it economics and healthcare expenditures, support conclusions regarding this controversial piece of legislation.

Related Reports:

Kalorama Information Library and Annual Subscription
Jan 1, 2010 - KLI1600708 - $55,000.00

EMR 2010 (Market Analysis, ARRA Incentives, Key Players, and Important Trends)
Dec 1, 2009 - KLI2503320 - $3,500.00

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
Oct 1, 2009 - KLI2435380 - $3,500.00

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Oct 1, 2009 - KLI2384194 - $3,995.00

Rx to OTC Switches 2009
May 1, 2009 - KLI2196300 - $3,500.00

World Veterinary Health Products (Animal Pharmaceuticals, Vaccines, OTC and Performance Enhancers)
May 1, 2009 - KLI1829596 - $3,500.00

Retail Clinics and the In-Store Healthcare Market 2009: Bright Spot in the Current Economy?
Mar 1, 2009 - KLI2041111 - $3,500.00

Women's Health: Worldwide Prescription Drug Markets
Feb 1, 2009 - KLI2071673 - $2,995.00

KTA Pharmaceutical, Device, Diagnostic Subscription
Jan 1, 2009 - KLI2482006 - $45,000.00

Pharmaceutical Outsourcing Post-Launch : Contract Manufacturing, Biomanufacturing and Sales, 3rd Edition
Jan 1, 2009 - KLI1646605 - $3,500.00